Search results
Jan 22, 2018 · Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category. The definitive terms...
Jan 22, 2018 · Juno is a pioneer in the development of CAR (chimeric antigen receptor) T and TCR (T cell receptor) therapeutics with a broad, novel portfolio evaluating multiple targets and cancer indications.
Jan 22, 2018 · (Reuters) - Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own...
Feb 5, 2021 · Juno Therapeutics, Inc. is a wholly owned subsidiary of Bristol-Myers Squibb Company. The approval of Breyanzi is based on a Biologics License Application that was submitted by Juno Therapeutics. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol Myers Squibb company ...
Nov 1, 2017 · David Crow. November 1 2017. Unlock the Editor’s Digest for free. Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Juno Therapeutics jumped by...
Feb 6, 2021 · FDA Approves Breyanzi to Juno Therapeutics, a BMS Company. Breyanzi i s the U.S. FDA’s fourth approval of a CAR-T cell therapy, which now include: Kymriah. Yescarta. Tecartus. Breyanzi. It is also the first regenerative medicine therapy with RMAT designation to be licensed by the FDA.
By Stephanie Saul. Celgene to Pay $1 Billion for Biotech Collaboration With Juno. As part of the deal, Celgene will acquire 9.1 million shares of Juno, a leader in cancer drugs that use...
